Cargando…
Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia
Although a 2 g once daily administration of ceftriaxone remains the standard dosing regimen for the treatment of aspiration pneumonia, there are no studies to investigate the optimal dosing method. Hence, we retrospectively evaluated the effectiveness and safety of 1 g twice daily versus 2 g once da...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331887/ https://www.ncbi.nlm.nih.gov/pubmed/35892373 http://dx.doi.org/10.3390/antibiotics11080983 |
_version_ | 1784758512392339456 |
---|---|
author | Kato, Hideo Hagihara, Mao Morikawa, Yoshihiko Asai, Nobuhiro Mikamo, Hiroshige Iwamoto, Takuya |
author_facet | Kato, Hideo Hagihara, Mao Morikawa, Yoshihiko Asai, Nobuhiro Mikamo, Hiroshige Iwamoto, Takuya |
author_sort | Kato, Hideo |
collection | PubMed |
description | Although a 2 g once daily administration of ceftriaxone remains the standard dosing regimen for the treatment of aspiration pneumonia, there are no studies to investigate the optimal dosing method. Hence, we retrospectively evaluated the effectiveness and safety of 1 g twice daily versus 2 g once daily administration of ceftriaxone in adult patients with aspiration pneumonia. Patients who received ceftriaxone for the treatment of aspiration pneumonia between 2015 and 2021 were included in this study. Clinical responses, inflammatory markers, and incidence of adverse events after completion of ceftriaxone therapy were investigated. In total, 33 patients received 1 g twice daily (group 1) and 28 received 2 g once daily (group 2) ceftriaxone for the treatment of mild-to-moderate aspiration pneumonia. Compared with that of group 1, group 2 demonstrated significantly improved clinical responses (group 1 vs. group 2, 84.8% vs. 100%, p = 0.0316). Although the safety profile was not significantly different between the two groups, the incidence of choleliths during ceftriaxone therapy in group 1 was higher than that in group 2 (31.3% vs. 9.1%, p = 0.174). Therefore, a 2 g once daily administration of ceftriaxone appeared to be a simple regimen adequate for the treatment of inpatients with mild-to-moderate aspiration pneumonia, which might not be heavily involved by anaerobes. |
format | Online Article Text |
id | pubmed-9331887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93318872022-07-29 Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia Kato, Hideo Hagihara, Mao Morikawa, Yoshihiko Asai, Nobuhiro Mikamo, Hiroshige Iwamoto, Takuya Antibiotics (Basel) Article Although a 2 g once daily administration of ceftriaxone remains the standard dosing regimen for the treatment of aspiration pneumonia, there are no studies to investigate the optimal dosing method. Hence, we retrospectively evaluated the effectiveness and safety of 1 g twice daily versus 2 g once daily administration of ceftriaxone in adult patients with aspiration pneumonia. Patients who received ceftriaxone for the treatment of aspiration pneumonia between 2015 and 2021 were included in this study. Clinical responses, inflammatory markers, and incidence of adverse events after completion of ceftriaxone therapy were investigated. In total, 33 patients received 1 g twice daily (group 1) and 28 received 2 g once daily (group 2) ceftriaxone for the treatment of mild-to-moderate aspiration pneumonia. Compared with that of group 1, group 2 demonstrated significantly improved clinical responses (group 1 vs. group 2, 84.8% vs. 100%, p = 0.0316). Although the safety profile was not significantly different between the two groups, the incidence of choleliths during ceftriaxone therapy in group 1 was higher than that in group 2 (31.3% vs. 9.1%, p = 0.174). Therefore, a 2 g once daily administration of ceftriaxone appeared to be a simple regimen adequate for the treatment of inpatients with mild-to-moderate aspiration pneumonia, which might not be heavily involved by anaerobes. MDPI 2022-07-22 /pmc/articles/PMC9331887/ /pubmed/35892373 http://dx.doi.org/10.3390/antibiotics11080983 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kato, Hideo Hagihara, Mao Morikawa, Yoshihiko Asai, Nobuhiro Mikamo, Hiroshige Iwamoto, Takuya Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia |
title | Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia |
title_full | Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia |
title_fullStr | Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia |
title_full_unstemmed | Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia |
title_short | Retrospective Comparison of the Effectiveness and Safety of Ceftriaxone 1 g Twice Daily versus 2 g Once Daily for Treatment of Aspiration Pneumonia |
title_sort | retrospective comparison of the effectiveness and safety of ceftriaxone 1 g twice daily versus 2 g once daily for treatment of aspiration pneumonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331887/ https://www.ncbi.nlm.nih.gov/pubmed/35892373 http://dx.doi.org/10.3390/antibiotics11080983 |
work_keys_str_mv | AT katohideo retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia AT hagiharamao retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia AT morikawayoshihiko retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia AT asainobuhiro retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia AT mikamohiroshige retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia AT iwamototakuya retrospectivecomparisonoftheeffectivenessandsafetyofceftriaxone1gtwicedailyversus2goncedailyfortreatmentofaspirationpneumonia |